NTLA
NASDAQ · Biotechnology
Intellia Therapeutics Inc
$10.68
-0.41 (-3.70%)
Open$11.13
Previous Close$11.09
Day High$11.19
Day Low$10.60
52W High$28.25
52W Low$7.95
Volume—
Avg Volume3.73M
Market Cap1.66B
P/E Ratio—
EPS$-3.53
SectorBiotechnology
Analyst Ratings
Buy
27 analysts
Price Target
+204.4% upside
Current
$10.68
$10.68
Target
$32.51
$32.51
$20.88
$32.51 avg
$45.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 97.21M | 89.11M | 223.20M |
| Net Income | -592,841,099 | -489,097,982 | -30,251,127 |
| Profit Margin | -609.9% | -579.4% | -13.6% |
| EBITDA | -619,462,902 | -539,453,439 | -52,265,042 |
| Free Cash Flow | — | — | -47,461,783 |
| Rev Growth | +9.1% | +9.1% | +19.1% |
| Debt/Equity | — | — | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |